Inactive Disease and Remission in Childhood-Onset Systemic Lupus Erythematosus

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorMINA, Rina
dc.contributor.authorKLEIN-GITELMAN, Marisa S.
dc.contributor.authorRAVELLI, Angelo
dc.contributor.authorBERESFORD, Michael W.
dc.contributor.authorAVCIN, Tadej
dc.contributor.authorESPADA, Graciela
dc.contributor.authorEBERHARD, B. Anne
dc.contributor.authorSCHANBERG, Laura E.
dc.contributor.authorO'NEIL, Kathleen M.
dc.contributor.authorSILVA, Clovis A.
dc.contributor.authorHIGGINS, Gloria C.
dc.contributor.authorONEL, Karen
dc.contributor.authorSINGER, Nora G.
dc.contributor.authorSCHEVEN, Emily von
dc.contributor.authorIMUNDO, Lisa F.
dc.contributor.authorNELSON, Shannen
dc.contributor.authorGIANNINI, Edward H.
dc.contributor.authorBRUNNER, Hermine I.
dc.date.accessioned2014-01-28T22:31:06Z
dc.date.available2014-01-28T22:31:06Z
dc.date.issued2012
dc.description.abstractObjective. To define inactive disease (ID) and clinical remission (CR) and to delineate variables that can be used to measure ID/CR in childhood-onset systemic lupus erythematosus (cSLE). Methods. Delphi questionnaires were sent to an international group of pediatric rheumatologists. Respondents provided information about variables to be used in future algorithms to measure ID/CR. The usefulness of these variables was assessed in 35 children with ID and 31 children with minimally active lupus (MAL). Results. While ID reflects cSLE status at a specific point in time, CR requires the presence of ID for >6 months and considers treatment. There was consensus that patients in ID/CR can have <2 mild nonlimiting symptoms (i.e., fatigue, arthralgia, headaches, or myalgia) but not Raynaud's phenomenon, chest pain, or objective physical signs of cSLE; antinuclear antibody positivity and erythrocyte sedimentation rate elevation can be present. Complete blood count, renal function testing, and complement C3 all must be within the normal range. Based on consensus, only damage-related laboratory or clinical findings of cSLE are permissible with ID. The above parameters were suitable to differentiate children with ID/CR from those with MAL (area under the receiver operating characteristic curve >0.85). Disease activity scores with or without the physician global assessment of disease activity and patient symptoms were well suited to differentiate children with ID from those with MAL. Conclusion. Consensus has been reached on common definitions of ID/CR with cSLE and relevant patient characteristics with ID/CR. Further studies must assess the usefulness of the data-driven candidate criteria for ID in cSLE.
dc.description.indexMEDLINE
dc.description.sponsorshipNational Institutes of Health (NIH) [U01-AR51868, U01-AR055054, P30-AR AR47363, P60-AR047884, UL1RR026314]
dc.description.sponsorshipNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIH-NIAMS) [T32100291]
dc.identifier.citationARTHRITIS CARE & RESEARCH, v.64, n.5, p.683-693, 2012
dc.identifier.doi10.1002/acr.21612
dc.identifier.eissn2151-4658
dc.identifier.issn2151-464X
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/4470
dc.language.isoeng
dc.publisherWILEY-BLACKWELL
dc.relation.ispartofArthritis Care & Research
dc.rightsrestrictedAccess
dc.rights.holderCopyright WILEY-BLACKWELL
dc.subject.otherjuvenile idiopathic arthritis
dc.subject.otherrheumatology provisional criteria
dc.subject.other13th international-congress
dc.subject.othercomplement component c4
dc.subject.otherapl tests report
dc.subject.otheramerican-college
dc.subject.otherantiphospholipid antibodies
dc.subject.otherpreconference workshop
dc.subject.otherselect categories
dc.subject.otherglobal flares
dc.subject.wosRheumatology
dc.titleInactive Disease and Remission in Childhood-Onset Systemic Lupus Erythematosus
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.affiliation.countryItália
hcfmusp.affiliation.countryArgentina
hcfmusp.affiliation.countryInglaterra
hcfmusp.affiliation.countryEslovênia
hcfmusp.affiliation.countryEstados Unidos
hcfmusp.affiliation.countryisous
hcfmusp.affiliation.countryisoit
hcfmusp.affiliation.countryisogb
hcfmusp.affiliation.countryisosi
hcfmusp.affiliation.countryisoar
hcfmusp.author.externalKLEIN-GITELMAN, Marisa S.:Childrens Mem Hosp, Chicago, IL 60614 USA
hcfmusp.author.externalRAVELLI, Angelo:Univ Genoa, Genoa, Italy; Ist Giannina Gaslini, Genoa, Italy
hcfmusp.author.externalBERESFORD, Michael W.:Univ Liverpool, Inst Translat Med, Liverpool L69 3BX, Merseyside, England; Alder Hey Childrens NHS Fdn Trust, Liverpool, Merseyside, England
hcfmusp.author.externalAVCIN, Tadej:Univ Childrens Hosp, Ljubljana, Slovenia; Univ Med Ctr Ljubljana, Ljubljana, Slovenia
hcfmusp.author.externalESPADA, Graciela:Univ Buenos Aires, Buenos Aires, DF, Argentina; Hosp Ninos Dr Ricardo Gutierrez, Buenos Aires, DF, Argentina
hcfmusp.author.externalEBERHARD, B. Anne:Steven & Alexandra Cohen Childrens Med Ctr New Yo, New York, NY USA
hcfmusp.author.externalSCHANBERG, Laura E.:Duke Univ, Med Ctr, Durham, NC USA
hcfmusp.author.externalO'NEIL, Kathleen M.:Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA
hcfmusp.author.externalHIGGINS, Gloria C.:Ohio State Univ, Columbus, OH 43210 USA; Nationwide Childrens Hosp, Columbus, OH USA
hcfmusp.author.externalONEL, Karen:Univ Chicago, Comer Childrens Hosp, Chicago, IL 60637 USA
hcfmusp.author.externalSINGER, Nora G.:MetroHlth Med Ctr, Cleveland, OH USA; Case Western Reserve Univ, Cleveland, OH 44106 USA
hcfmusp.author.externalSCHEVEN, Emily von:Univ Calif San Francisco, San Francisco, CA 94143 USA
hcfmusp.author.externalIMUNDO, Lisa F.:Columbia Univ, Med Ctr, New York, NY USA; Childrens Hosp New York, New York, NY USA
hcfmusp.author.externalBRUNNER, Hermine I.:Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, William S Rowe Div Rheumatol, Cincinnati, OH 45229 USA
hcfmusp.citation.scopus29
hcfmusp.contributor.author-fmusphcCLOVIS ARTUR ALMEIDA DA SILVA
hcfmusp.description.beginpage683
hcfmusp.description.endpage693
hcfmusp.description.issue5
hcfmusp.description.volume64
hcfmusp.lim.ref2012
hcfmusp.origemWOS
hcfmusp.origem.pubmed22238253
hcfmusp.origem.scopus2-s2.0-84861112450
hcfmusp.origem.wosWOS:000305790500006
hcfmusp.publisher.cityHOBOKEN
hcfmusp.publisher.countryUSA
hcfmusp.relation.referenceBertolaccini ML, 2011, LUPUS, V20, P191, DOI 10.1177/0961203310397082
hcfmusp.relation.referenceBoers Maarten, 2010, Bull NYU Hosp Jt Dis, V68, P140
hcfmusp.relation.referenceBoers M, 1998, J RHEUMATOL, V25, P198
hcfmusp.relation.referenceBruce IN, 2010, CURR OPIN RHEUMATOL, V22, P273, DOI 10.1097/BOR.0b013e3283374e78
hcfmusp.relation.referenceBrunner HI, 2008, ARTHRITIS RHEUM, V58, P556, DOI 10.1002/art.23204
hcfmusp.relation.referenceBrunner HI, 2011, ARTHRIT CARE RES, V63, P1213, DOI 10.1002/acr.20507
hcfmusp.relation.referenceBrunner HI, 1999, ARTHRITIS RHEUM, V42, P1354, DOI 10.1002/1529-0131(199907)42:7<1354::AID-ANR8>3.0.CO;2-4
hcfmusp.relation.referenceBrunner HI, 2010, ARTHRIT CARE RES, V62, P811, DOI 10.1002/acr.20126
hcfmusp.relation.referenceCheung K L, 2003, Minerva Chir, V58, P297
hcfmusp.relation.referenceChung EK, 2002, AM J HUM GENET, V71, P823, DOI 10.1086/342777
hcfmusp.relation.referenceClassification and Response Criteria Subcommittee of the American College of Rheumatology Committee on Quality Measures, 2006, ARTHRITIS RHEUM, V55, P348
hcfmusp.relation.referenceDelbecq A. L., 1975, GROUP TECHNIQUES PRO
hcfmusp.relation.referenceEyer-Silva WA, 2002, AIDS, V16, P2367, DOI 10.1097/00002030-200211220-00031
hcfmusp.relation.referenceFelson DT, 2011, ARTHRITIS RHEUM-US, V63, P573, DOI 10.1002/art.30129
hcfmusp.relation.referenceGalambos J., 1996, BONFERRONI TYPE INEQ
hcfmusp.relation.referenceHANLEY JA, 1982, RADIOLOGY, V143, P29
hcfmusp.relation.referenceHiraki LT, 2008, J PEDIATR, V152, P550, DOI 10.1016/j.jpeds.2007.09.019
hcfmusp.relation.referenceHochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928
hcfmusp.relation.referenceKasitanon N, 2006, MEDICINE, V85, P147, DOI 10.1097/01.md.0000227709.70133.f7
hcfmusp.relation.referenceKlein-Gitelman M, 2002, RHEUM DIS CLIN N AM, V28, P561, DOI 10.1016/S0889-857X(02)00015-7
hcfmusp.relation.referenceLANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
hcfmusp.relation.referenceLovell DJ, 2011, ARTHRIT CARE RES, V63, P10, DOI 10.1002/acr.20348
hcfmusp.relation.referencePierangeli SS, 2011, LUPUS, V20, P182, DOI 10.1177/0961203310395055
hcfmusp.relation.referenceRuiz-Irastorza G, 2010, ANN RHEUM DIS, V69, P20, DOI 10.1136/ard.2008.101766
hcfmusp.relation.referenceRuperto N, 2006, ARTHRIT RHEUM-ARTHR, V55, P355, DOI 10.1002/art.22002
hcfmusp.relation.referenceRuperto N, 2004, CURR OPIN RHEUMATOL, V16, P566, DOI 10.1097/01.bor.0000130286.54383.ea
hcfmusp.relation.referenceShtatland ES, 1998, P LOGISTIC SUGI 98 P, P1194
hcfmusp.relation.referenceUrowitz MB, 2005, J RHEUMATOL, V32, P1467
hcfmusp.relation.referenceWallace CA, 2011, ARTHRIT CARE RES, V63, P929, DOI 10.1002/acr.20497
hcfmusp.relation.referenceWallace CA, 2004, J RHEUMATOL, V31, P2290
hcfmusp.relation.referenceYang Y, 2007, AM J HUM GENET, V80, P1037, DOI 10.1086/518257
hcfmusp.relation.referenceYang Y, 2004, CURR DIRECT AUTOIMMU, V7, P98
hcfmusp.remissive.sponsorshipNIH
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublication6c3c5459-9dbb-4a5c-98b1-d7b76943b87d
relation.isAuthorOfPublication.latestForDiscovery6c3c5459-9dbb-4a5c-98b1-d7b76943b87d
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_SILVA_Inactive_Disease_and_Remission_in_Childhood_Onset_Systemic_2012.PDF
Tamanho:
113.98 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - HC/ICr
Artigos e Materiais de Revistas Científicas - LIM/36